Comparative Pharmacology
Head-to-head clinical analysis: OBREDON versus TENORETIC 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OBREDON versus TENORETIC 100.
OBREDON vs TENORETIC 100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clonidine is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the central nervous system, leading to decreased peripheral vascular resistance and blood pressure.
Tenoretic 100 is a combination of atenolol (a cardioselective beta-1 adrenergic receptor antagonist) and chlorthalidone (a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule). Atenolol reduces heart rate, cardiac output, and blood pressure by blocking beta-1 receptors; chlorthalidone reduces plasma volume and peripheral resistance.
Adults: 10 mg orally once daily. For patients requiring more rapid relief, initial dose of 20 mg once daily may be used; switch to 10 mg once daily after 4 to 8 weeks.
One tablet orally once daily, each tablet containing atenolol 100 mg and chlorthalidone 25 mg. May be increased to 2 tablets once daily if needed.
None Documented
None Documented
Terminal elimination half-life of 30 hours (range 24-36 hours), supporting once-daily dosing in chronic therapy.
Atenolol: terminal half-life 6-7 h (up to 14 h in severe renal impairment); Chlorthalidone: 40-60 h (long-acting diuretic).
Approximately 75% renal excretion as unchanged drug and metabolites, with 25% fecal elimination via biliary secretion.
Tenoretic 100 (atenolol 100 mg + chlorthalidone 25 mg): Atenolol: ~85% renal unchanged, <10% fecal; Chlorthalidone: ~65% renal unchanged, remainder biliary/fecal.
Category C
Category C
Beta blocker/alpha blocker
Beta blocker/thiazide diuretic combination